In conclusion, our genetic analysis predicts that in a broader dyslipidaemic patient population, therapies aimed at decreasing plasma ANGPTL3, ANGPTL4, or APOC3 levels will be effective in preventing CAD without raising specific safety concerns. The gene discussed is ANGPTL3; the disease is coronary artery disorder.